

UNIVERSITÀ DEGLI STUDI DI TRIESTE

BIOMARCATORI NEI TESSUTI

Serena Bonin Dipartimento di Scienze Mediche, Chirurgiche e della Salute Università degli Studi di Trieste



Quality of Clinical samples

Clinical tissues

Biomarkers' definition and classification

Analytical Methods



Sources of Clinical research and Diagnostic Variabiliy

Tissue and macromolecule pre-analytical preservation
 Heterogeneity at the clinical, morphological or molecular level
 Selection and standardization of analytical procedures
 SOPs

What are pre-analytical conditions? How do they affect analytical results? How can quality of samples be assured?

Why pre-analytics?

Physicians rely on accurate laboratory test results for diagnosis and guiding therapy: more than 70% of clinical decisions are based from information derived from laboratory results (MLO Med Lab Obs. 2014 May;46(5):22, 24, 26)

> 10^7 € of funding may be lost each year in clinical trials in the EU due to pre-analytical and analytical problems (<u>Ann Transl Med.</u> 2016 May;4(9):181)



What is pre-analytics?

Pre-analytical phase: covers all steps from the clinicians requests to the beginning of the analytical examination, included nucleic acid or protein extractions



Why extractions into pre-analytics?



Why pre-analytics?

Standardization of pre-analytical processes is key to guarantee reliability of analytical results

Same requirements for diagnostics and biobanks

Increasing demand in the context of personalized medicine and companion diagnostics
European healthy subjects



Serum from 5 biobanks

EDTA-plasma from 9 biobanks

Why pre-analytics?

Medical research irreproducibility, which slows down the translation into medical practice



Sources of variability related to clinical research irreproducibility #Tissue and macromolecule pre-analytical preservation (pre- and fixation procedures) #Selection and standardization of analytical procedures (standardization of procedures, controls, interpretation of results) #Heterogeneity on morphological and molecular level

The Economist. 2013 Oct How Science goes wrong

Major efforts for improvement

- Technologies for securing high quality samples
- International Standards for pre-analytical workflows

What is a standard?

It is a reference model to which you may conform.

The standard or norm is a document, used in various areas, which establishes technical specifications for the realization of a product or the provision of a service.

Those documents are created by International normation bodies-

CEN and ISO and the National counterparts.

https://youtu.be/XMjQY2QzZ_U?list=PLdF-

<u>R TmJXfgqxLlcUfEml45 Ph 55ECe</u>

Pre-analytical Workflow - Standards for all Segment

O Biobanks

• Source for high quality samples BBMRI-ERIC plays a central role

Biomedical & Translational Research

- Academia
- Pharma industry
- Diagnostic Industry

• O Diagnostics

- High sample quality is mandatory for reliable diagnostic results
- Analytical assay might tolerate lower quality or not
 →Validation studies

VISO 20184-2:2018

Molecular in vitro diagnostic examinations -- Specifications for pre-examination processes for frozen tissue Isolated proteins

VISO 20184-1:2018

Molecular in vitro diagnostic examinations -- Specifications for pre-examination processes for frozen tissue Isolated RNA

VISO 20166-2:2018

Molecular in vitro diagnostic examinations -- Specifications for pre-examinations processes for formalin-fixed and paraffin-embedded (FFPE) tissue Isolated proteins

VISO 20166-1:2018

Molecular in vitro diagnostic examinations -- Specifications for pre-examination processes for formalin-fixed and paraffin-embedded (FFPE) tissue Isolated RNA

VISO 20166-3:2018

Molecular in vitro diagnostic examinations -- Specifications for pre-examination processes for formalin-fixed and paraffin-embedded (FFPE) tissue Isolated DNA

VISO 20186-3:2019

Molecular in vitro diagnostic examinations -- Specifications for pre-examination processes for venous whole blood Isolated circulating cell free DNA from plasma

ISO 20186-1:2019

Molecular in vitro diagnostic examinations -- Specifications for pre-examination processes for venous whole blood Isolated cellular RNA

VISO 20186-2:2019

Molecular in vitro diagnostic examinations -- Specifications for pre-examination processes for venous whole blood Isolated genomic DNA

ISO Technical Specification for FFPE tissues

Contents

Page

European foreword				
Introduction				
1	Scope			
2	Normative references			
3	Terms and definitions			
4	General considerations			
5 5.1 5.1.1 5.1.2 5.1.3 5.2	Outside the laboratory Primary tissue collection manual Information about the primary sample donor Information on the primary tissue sample Information on the primary tissue sample processing Transport requirements	8 8 8 8 8 9		
6 6.1 6.2 6.3	Inside the laboratory Information on the primary tissue sample receipt Formalin fixation of the specimen Evaluation of the pathology of the specimen and selection of the sample. Part fixed of the sample.			
6.4 6.5 6.6	Processing and paraffin embedding	11 12		
6.7 6.7.1	Isolation of the total RNA	12 12		
6.7.2 6.7.3 6.7.4 6.8	Using commercial kits			
6.9 Annex	A (informative) Quality control of RNA extracted from formalin fixed and paraffin embedded tissue samples: implications for RT_REPORT based analyses	14		
A.1	Summary	15		
A.2	Results	15		
A.2.1	Time dependency of RNA integrity	15		
A.2.2	Impact of formalin-fixation on cDNA synthesis efficiency	16		
A.2.3	Fixation and storage introduces major gene-to-gene variations in RT-gPCR			
A.2.4	Impact of storage conditions of FFPE blocks on RNA Integrity			
A.3	Conclusions	18		
A.4	Further reading	19		
Bibliog	araphy	20		

International Standards (ISO) and European Technical Specifications (CEN) BBMRI-ERIC Self-Assessment Survey



www.bbmri-eric.eu/services/quality-management/



IARC: 2 Italy: 10 Latvia: 3

Malta: 6

UK: 1

BBMRI-ERIC Work Programme 2016-2020 CEN/TC 140 and ISO/TC 212 Molecular in vitro diagnostic examinations – Specifications for pre-examination processes

Representatives of Quality Experts Groups: Austria: 18 Belgium: 19 Bulgaria: 1 Switzerland: 4 Cyprus: 3 Czech Republic: 3 Germany: 15 Estonia: 3 Finland: 20 Greece: 1 Lithuania: 1 Netherlands: 4 Norway: 6 Poland: 10 Sweden: 6 Turkey: 12



MEMBERS OF BBMRI-ERIC **OBSERVERS OF BBMRI-ERIC**

BBMRI-ERIC Self-Assessment Survey www.bbmri-eric.eu/services/quality-management/

ACCESS TO BBMRI-ERIC SAS

REQUEST FOR A SELF-ASSESSMENT SURVEY

• GO TO

bbmri-eric.eu/services/self-assessment-survey/

 FILL OUT Request form / tick off pre-conditions / send

 GET STARTED Receive @ with the link to SAS

EVALUATION OF SPECIFICATIONS

 COMPLETION of BBMRI-ERIC SAS

 SUBMIT REPORT to **BBMRI-ERIC**

 BE REVIEWED by BBMRI-ERIC (remote or on-site)

AWARD Q-LABEL IN BBMRI-ERIC DIRECTORY

 SAMPLE COLLECTION Assessed according to relevant standards

 BIOBANK Internal audit based on ISO 20387 and ISO 9001

 ENHANCE VISIBILITY Q-Label in the Directory directory.bbmri-eric.eu

Please fill in your contact information: *Name *E-mail address *Affiliation

*Address/Country

Please provide us with some information by answering the following questions:

* Is your organisation located in a BBMRI-ERIC Member/Observer State? See http://www.bbmri-eric.eu/national-nodes/ ○ Yes ○ No

* Are you in contact with the coordinating office from the National Node in your country? See http://www.bbmrieric.eu/national-nodes/

○ Yes ○ No

* Have you purchased the required ISO and CEN/TS standards, as the basis for your biobanking and specimen handling procedures? See http://www.bbmri-eric.eu/services/standardisation/

○ Yes ○ No

* Please select the required BBMRI-ERIC Self-Assessment Surveys from the list below:

Quality Management Systems - General Requirements for Biobanking

- Specifications for pre-examination processes for frozen tissue Part 1: Isolated RNA; ISO 20184-1:2018
- Specifications for pre-examination processes for frozen tissue Part 2: Isolated proteins; ISO 20184-2:2018
- Specifications for pre-examination processes for FFPE tissue Part 1: Isolated RNA; CEN/TS 16827-1:2015 (will be replaced soon with ISO 20166-1:2018)
- Specifications for pre-examination processes for FFPE tissue Part 2: Isolated proteins; CEN/TS 16827-2:2015 (will be replaced soon with ISO 20166-2:2018)
- Specifications for pre-examination processes for FFPE tissue Part 3: Isolated DNA; CEN/TS 16827-3:2015 (will be replaced soon with ISO 20166-3:2018)
- Specifications for pre-examination processes for venous whole blood Part 1: Isolated cellular RNA; CEN/TS 16835-1:2015 (will be replaced during 2020 with ISO 20186-1:2019)
- Specifications for pre-examination processes for venous whole blood Part 2: Isolated genomic DNA; CEN/TS 16835-2:2015 (will be replaced during 2020 with ISO 20186-2:2019)
- Specifications for pre-examination processes for venous whole blood Part 3: Isolated circ. cell-free DNA from plasma; CEN/TS 16835-3:2015 (will be replaced during 2020 with ISO 20186-3:2019)
- □ Specifications for pre-examination processes for Metabolomics in urine; CEN/TS 16945:2016
- Specifications for pre-examination processes for Metabolomics in serum and plasma; CEN/TS 16945:2016

10	Southing and Annual Southing a	BBMRI-ER
		i Isu
	rmation about the specimen donor/patient	
	Donor/patient ID was documented shall	⊖ Yes ⊖ No
		e.g. in form of a code
	a) Health status of donor/patient was documented should	 Yes No e.g. healthy, disease type, concomitant disea. demographics (e.g. age, gender)
	b) Routine medical treatment prior to tissue collection was documented should	 Yes No reset e.g. anaesthetics, medications, surgical or diagnostic procedures
	c) Appropriate consent from donor/patient was documented should	○ Yes ○ No reset
3. I	nformation about the specimen	
	a) Start of ischemia within the body (warm ischemia) - ischemia-relevant vessel ligation/clamping time point (usually arterial clamping time) - was documented shall	 Yes No Not applicable, not needed where small tissue biopsy resection for freezing is performed
	b) Time, date and method of removal were documented shall	 Yes No e.g. core-needle biopsy, resection, biopsy
	c) Tissue type, origin and condition were documented shall	 used for the collection Yes No e.g. diseased, unaffected ⁺

BBMRI-ERIC Self-Assessment Survey

SPIDIA for personalised medicine: Standardisation and improvement of generic pre-analytical tools and procedures for in-vitro diagnostics



✓ 48-month project

- ✓ key experts of 19 stakeholder organisations
- Aims: pre-analytical procedures, European and international standardisation organisations' processes (CEN and ISO), external quality assurance, quality management, ethics and regulatory demands

✓ <u>www.spidia.eu</u>

CEN Technical Specifications for Pre-examination Processes



Development of 12 new CEN/TS and 2 ISO standards & Raising awareness for and implementation of standards

4 Venous whole blood circul. tumor cells — RNA, DNA, protein & staining
procedures
1 Venous whole blood exosomes — cfc RNA
1 Frozen tissue — DNA
1 Urine/other body fluids - cfcDNA
3 fine needle aspirates – RNA, DNA, protein
1 Saliva & stool microbiomes– DNA CEN/TS
1 Saliva — DNA

1 FFPE tissue – in-situ staining
 1 Metabolomics – urine, plasma, serum

ISO



13 new External Quality Assurance Schemes corresponding to the preanalytical standards portfolio

- Venous Whole Blood: Genomic DNA and cellular RNA, viable PBMC, Cell Free Circulating DNA(ccfDNA), Cell Free Circulating RNA (ccfRNA), Circulating Tumour Cells (CTCs)
- ✓ FFPE tissue : DNA, RNA, protein
- ✓ Frozen tissue: Genomic DNA, RNA, protein
- ✓ Saliva: DNA
- ✓ Stool: DNA